CTAG2 (encodes cancer-testis antigen 2) and MAGEA1 were shown to be expressed consistently in myeloid and round-cell liposarcomas [48]; hence, these genes are used as immunotherapy targets in the treatment of these cancers. This evidence concerns the gene MAGEA1 and cancer.